Biotech and Pharma stocks News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Completes Both Pivotal LibiGel® Efficacy Trials


LINCOLNSHIRE, Ill. - October 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). The final visit of the last subject enrolled in the second of the two pivotal LibiGel Phase III efficacy trials occurred at the end of September. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

Data are being collected from the 141 investigative sites in the U.S. and Canada that participated in the two trials, and BioSante expects to announce top-line LibiGel efficacy results during this quarter. Both efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA). The third and last pivotal study for the LibiGel clinical development program is the ongoing LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of 3,656 subjects. The primary analysis of safety data is targeted for third quarter of 2012. The LibiGel NDA submission will include data from the two efficacy trials as well as the safety study and is targeted for the fourth quarter of 2012.
"We are delighted to have completed both LibiGel Phase III efficacy trials. We appreciate the diligence of the investigative sites and their care of the subjects in the trials, and we also thank the participating subjects," noted Joanne Zborowski, BioSante's vice president of clinical development. "There were over 1,100 subjects enrolled in the two efficacy trials, and we look forward to analyzing the data and announcing the results later this year."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The completed Phase III efficacy trials are double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from HSDD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued over 4,800 women-years of exposure, to date. The study will continue for a total of five years; however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to demonstrate the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval of LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the fourth quarter of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to its future operations and products, the timing of anticipated clinical development milestones and regulatory submissions and other statements identified by words such as �anticipates,� �expects,� �will,� �continue,� �could,� �believes,� �intends,� �estimates,� �may,� other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com

The Renewable Energy Stock That Could... Ener1 Inc (NasdaqGS: HEV) Momentum Continues as Stock Moves over 23% in Morning Trading

Point Roberts, WA - October 4, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, issues a morning trading alert for Ener1 Inc (NasdaqGS: HEV). The stock has been on the run for days and continues its gains in todat's morning session, trading at $0.2298, up another 0.0443 (23.88%) 10:15AM EDT.

Ener1 Inc (NasdaqGS: HEV) is one of the renewable energy stocks that had been battered to its lows with lawsuits, and losses from its 52 week-high of $5.90. The Company has recently announced changes in management and is obviously on a new path with new leadership. Is this a sign and signal for some of the other companies in the sector, in particular some of the solar stocks?
According to our solar expert J Peter Lynch in his commentary yesterday, he is still optimistic for the future of solar stocks and solar technology and he thinks the stocks will tell investors the time to buy . Read yesterday's article : http://www.investorideas.com/PL/news/ 2011/10031.asp
5 Day chart for HEV
Use the renewable energy stocks directory to research 1300 green stocks on global stock exchanges http://www.investorideas.com/Companies/ RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit Investorideas.com green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/ RenewableEnergy/ or www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com contact:
800.665.0411

Pharma/Biotech Stock (OTC: AEMD) Doubles During Monday's Trading Following Report of $6.8 Million DARPA Contract


Point Roberts, WA - October 4, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, reports Aethlon Medical (OTCBB: AEMD) stock traded up over 100% , as high as $0.12 in yesterday's trading session following news of a $6.8 Million DARPA contract.

The stock traded significant volume and was one of the top ten percentage gainers on OTCBB throughout the day’s trading session on larger than normal trading volume. (See 5-day chart)
The Company reported yesterday that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. The contract program will utilize the Aethlon ADAPT™ system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.
Biotech Investor Snapshot for Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon's ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/ AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/ Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/ Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011       
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Monday's NASDAQ Winners: IIN, PPDI, MDCO, HEV

POINT ROBERTS - October 4, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday October 03rd. Nasdaq ended lower by 79.57 (-3.29%) to 2,335.83.

Yes investors, there are still winners even on another dismal day of market retreat.
IntriCon Corporation (NASDAQ:IIN) was the top percentage gainer for the session closing higher by 1.07 (34.85%) to $4.14 after the company announced it has entered into a manufacturing agreement to become hi HealthInnovations' supplier of hearing aids.
Pharmaceutical Product Development (NASDAQ:PPDI) surged 6.62 (25.80%) to close at $32.28 after the company agreed to go private affiliates of Carlyle Group and Hellman & Friedman for $3.9 billion, payable in cash.
The Medicines Company (NASDAQ:MDCO) closed with an impressive gain of 1.72 (11.56%) to end the day at $16.60 after it announced launch of a new twelve hour formulation for Cleviprex® (clevidipine) Injectable Emulsion, which was approved by the U.S. Food and Drug Administration (FDA) in June 2011. The stock is continuing its gains in early morning trading.
Renewable energy stock, Ener1, Inc. (NASDAQ:HEV) continued to move higher and ended at $0.185, up 0.12 049(35.40%). The stock has more than doubled in the past couple of trading sessions on sharp bounce back from its lows.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Biotech Stock News Alert; (OTC: AEMD) Trading Up 50.88% on News of $6.8 million Contract from Defense Advanced Research Projects Agency (DARPA)

Point Roberts, WA - October 3, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, report Aethlon Medical (OTCBB: AEMD), a pioneer in developing therapeutic filtration devices is trading up at $0.0860, up 0.0290 (50.88%) on over 1.3 million shares in early morning trading.
The Company reported news that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. The contract program will utilize the Aethlon ADAPT™ system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.
Biotech Investor Snapshot for Aethlon Medical (OTCBB: AEMD)

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon's ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/ AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/ Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/ Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011       
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Friday's NASDAQ Winners: CISG, AMSC, INFI, CAMP

POINT ROBERTS - October 3, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Friday September 30th. Nasdaq ended lower by 65.36 (-2.63%) to close at 2,415.40.

CNinsure Inc. (NASDAQ:CISG) was the top percentage gainer for the session closing higher by 1.06 (17.85%) to $7 as it bounced back from its 52-week low of $5.81. Volume was heavy with more than 780K shares traded, compared to its average volume of 725K shares. The Company distributes a wide variety of property and casualty and life insurance products underwritten by domestic and foreign insurance companies operating in China, and provides insurance claims adjusting as well as other insurance-related services.
Insurance stocks have been in the top NASDAQ gainers over the past few weeks with companies like Harleysville Group Inc. (NASDAQ:HGIC) announcing mergers.
American Superconductor Corporation (NASDAQ:AMSC) moved up 0.36 (12.63%) to close at $3.21. The company reported that it earned 11 cents a share on revenue of $33.8 million, compared to analysts’ estimates of 3 cents a share on revenue of $33.38 million.
The company projects to earn $30-$34 million in revenue for the current quarter.
Infinity Pharmaceuticals Inc (NASDAQ:INFI) closed with a gain of 0.71 (11.20%) to end the day at $7.05, bouncing back from its recent fall of 8% during the past week.
CalAmp Corp. (NASDAQ:CAMP) continued to move higher and ended at $3.21, up 0.36 (12.63%) after rallying about 6% in the previous trading session. The stock has a 52-week range of $2.34-$3.98.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Real time alerts, stock directories, investing ideas
Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Friday's Electric Car Stocks Trading; (OTC: EVCA), (NASDAQ: HEV), (OTC: LMCO), (NASDAQ: TSLA)

Point Roberts, WA - October 3, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on microcap, small cap and large cap electric car stocks trading for Friday30th September.

Ener1, Inc. (NASDAQ:HEV) was the biggest gainer and soared 52.22% to $0.137, bouncing from its recent lows on heavy volume of 10.19 million shares - 5X its average volume. The stock continues its gains in Monday morning trading, up another 7%.
EVCARCO (OTCBB: EVCA ) shares ended flat at 0.0024 with 100K shares traded hands. The Company is engaged in selling environmentally conscious automobiles, offering both new electric and pre-owned vehicles, and plan to offer related financing, warranties, maintenance, and mechanical services.
Li-ion Motors Corp (OTC:LMCO) was one of the biggest gainers and surged 0.030 (13.64%) to $0.25 with more than 61K shares traded hands, 1.50X its average volume. The stock has a 52-week range of $0.14-$1.20.
Tesla Motors, Inc. (NASDAQ: TSLA) gained 0.27 (1.12%) to $24.39 on over 1.33 million shares.
Cambria Automobiles PLC (LON:CAMB) surged 1.00 (4.17%) to $25.
Valence Technology, Inc. (NASDAQ:VLNC) added 0.04 (4.00%) to $1.04
Electric Car/ Green Car Company Snapshot
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
Visit the EVCA profile at Investorideas.com - http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks on Facebook.com
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information contact:
800 665 0411
Source: www.Investorideas.com

Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Receives Government Contract Award from DARPA

SAN DIEGO � October 3, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. The contract program will utilize the Aethlon ADAPT™ system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.

"We are truly honored to receive this contract award and look forward to working with DARPA and other DLT team participants to advance this important therapeutic endeavor," stated Aethlon Medical Chairman and CEO, Jim Joyce. "The award also reinforces the expansive capabilities of our ADAPT™ system, increases the breadth of our product pipeline, and transitions us from a development-stage to revenue-stage organization."
The Aethlon ADAPT™ system, introduced earlier this year, is an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that selectively target the clearance of harmful agents from the entire circulatory system without the loss of essential blood components. Therapies that evolve from the Aethlon ADAPT™ system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technology as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies. Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT™ therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics. As Aethlon advances its current pipeline of therapies toward market, the company will seek to further leverage its ADAPT™ system to generate revenue through future government contracts or grants, and collaborations with organizations representing the pharmaceutical, biotechnology and medical device industry. The Aethlon award from DARPA is a fixed price five-year contract valued at $6,794,389 with year one revenues of approximately $2 million.
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Pharma/Biotech stocks News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Cancer Immunotherapy Conference

LINCOLNSHIRE, Ill. - October 3, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 6, 2011, at the New York Academy of Medicine in New York. The single-day conference event unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy.

Stephen M. Simes, BioSante's president & chief executive officer, will speak at 1:45 pm EDT, and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials.
The conference will be hosted by MD Becker Partners and sponsored by JMP Securities, Thompson Hine, Roth Capital Partners and Cantor Fitzgerald. There will be a corresponding live webcast of the presentations, which can be accessed by visiting www.regonline.com/mdbpartners. A replay will be available for 30 days.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
About MD Becker Partners
MD Becker Partners LLC is a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry. As a strategic advisor and partner, the firm provides a full range of services to help clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, MD Becker Partners integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visit www.mdbpartners.com.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com

Renewable Energy Stocks Trading Alert; Ener1 Inc (NasdaqGS: HEV) Trading up 55%

Point Roberts, WA - September 30, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, issues a trading alert for Ener1 Inc (NasdaqGS: HEV). The stock is trading at 0.14, up 0.05 (55.56%).
Earlier this week the company reported, "Ener1, Inc. (NASDAQ:HEV), a leader in lithium-ion energy storage solutions, today announced two changes to its senior leadership team. Board member Thomas J. Snyder is replacing Charles Gassenheimer as chairman by assuming the role of non-executive chairman of the board. Chris Cowger, who has been serving as president of Ener1, will take over as chief executive officer from Mr. Gassenheimer, who is leaving the company. The changes are effective immediately. Mr. Gassenheimer is also expected to resign from Ener1's board of directors."
Use the renewable energy stocks directory to research 1300 green stocks on global stock exchanges http://www.investorideas.com/Companies/ RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit Investorideas.com green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com

Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/ Resources/ Newsletter.asp
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com contact: 800.665.0411

Thursday's Renewable Energy Stocks Trading; (OTC: CWET), (TSX.VCTW), (NASDAQ:FSLR), (NYSE:MY)

Point Roberts, WA - September 30, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on trading for small and large cap renewable energy stocks trading and news for September 29th.

Wind stock, Clean Wind Energy Tower Inc (OTCBB: CWET) shares ended flat at $0.15. This week the Company made two announcements on changes in business operations and share structure. They reported they are closing their internally staffed engineering office in Warrenton, Virginia and transitioning to a Development Team that will oversee and coordinate the efforts of industry consultants and advisors to develop and construct their first Dual Renewable Energy Tower. The company has also canceled share certificates held by "Former Employees", totaling 120,600,000 shares of common stock, following their resignations. The Company feels both developments are positive for the company and shareholders.
Wind stock, Catch the Wind Ltd. (TSX.V: CTW) soared 31.25% to $0.210 on light volume of over 31,000 shares. The Company develops and manufactures the Vindicator® laser wind sensor. The Vindicator® laser wind sensor is part of Catch the Wind's "next generation" turbine control and performance enhancement system for utility-scale wind turbines.
China Recycling Energy (NasdaqGM: CREG ) closed at $1.05, up 0.5 or 16.67%.The Company provides environmentally friendly waste-to-energy technologies to recycle industrial byproducts for steel mills, cement factories and coke plants in China.
First Solar, Inc. (NASDAQ:FSLR) jumped 0.43% to $65.03 following a 25% fall in the past week. The stock recently made a new 52-week low of $61.55. The stock is down over 50% so far this year.
American Superconductor Corporation (NASDAQ:AMSC) surged on news up 0.58 (14.95%) to close at $4.46, rebounding from its new 52-week low of $3.85 made earlier in the session. Korea Electric Power Corporation (KEPCO), LS Cable & System and American Superconductor announced that the world’s longest distribution-voltage superconductor cable system has been energized at the I’cheon substation located near the city of Seoul. Powered by AMSC’s Amperium™ superconductor wire and installed in Korea Electric Power Company’s (KEPCO) electricity grid, the 22.9 kV alternating current (AC) cable system is capable of carrying approximately 50 megawatts of power. This is longest HTS cable in the world to be energized in the grid utilizing second generation (2G) superconductor wire and is also currently the longest distribution voltage superconductor power cable in operation.
China Ming Yang Wind Power Group (NYSE:MY ) shares jumped over 4% in after-hours following a fall of 8.74% in the regular session. The stock has been trading lower over the past one month with other stocks within the sector.
More Research: get a full list of global publicly traded green stocks
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure - cwet is a paid advertising client on Investorideas.com green portals, 1500 per month and owns 100,000 shares
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information contact: 800 665 0411
Source: www.Investorideas.com

Thursday's NASDAQ Top Gainers: HGIC, AMSC, EMCI, CDII

POINT ROBERTS - September 30, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Thursday September 29th. Nasdaq ended lower by - 10.82 (-0.43%) to 2,480.76.

Harleysville Group Inc. (NASDAQ:HGIC) was the top percentage gainer for the session closing higher by 27.44 (87.06%) to a new 52-week high $58.96 after Nationwide Mutual Insurance Co. Nationwide agreed to acquire the company for $60 per share in cash.
American Superconductor Corporation (NASDAQ:AMSC) surged 0.58 (14.95%) to close at $4.46, rebounding from its new 52-week low of $3.85 made earlier in the session. So far this year, the stock has slumped over 84%.
EMC Insurance Group Inc. (NASDAQ:EMCI) closed with an impressive gain of 2.27 (13.69%) to end the day at $18.85 following 10% fall in the past week. Analyst at Zacks Investment Research reiterated their “underperform” rating on the stock.
China Direct Industries, Inc. (NASDAQ:CDII) continued to move higher and ended at $1.00, up 0.12 (13.64%). China Direct Industries, Inc. insiders have bought a total of 219,000 shares in the open market between 9/21/2011-9/26/2011.
Investor Ideas Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Stock Directories, real time alerts
Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Consumer Electronic Stock News; Nyxio Technologies (OTCBB:NYXO) Appoints Director of Asian Operations

PORTLAND, OR - September 30, 2011 (Investorideas.com Tech stocks newswire) - Nyxio Technologies Corporation (OTC.BB: NYXO.PK) ("Nyxio" or the "Company"), a leading provider of cutting edge "Smart TV" and consumer electronics products, is very pleased to welcome Janny Peng as Director of Asian Operations just as the Company commences strategic plans for entry into the Chinese marketplace where recent estimates place over 32 million "Smart TVs" to be sold over traditional televisions by 2015 (a 54% market share).

Reporting to Paul Higby, VP of Global Operations and ultimately to David Dabau, Company COO, Ms. Peng brings over 10 years of marketing and management experience and ongoing success in sales, manufacturing, product development, operations and logistics within markets across Asia and parts of the Russian Federation.
In China, she was most recently the overseas marketing director at Clover Industrial Co. Ltd., a manufacturer of tablet PCs, USB flash drives and digital photo frames. Previously she held a similar role with UTU Technology Group Ltd., a manufacturer of all-in-one PCs, LCD and LED televisions. Prior to this she enjoyed an excellent record in major sales as well as various related positions at G. Credit Industrial (SZ) Co. Ltd., and Shenzhen Shitai Co. Ltd.
Ms. Peng received her BA at Wuhan University, Hubei, Peoples Republic of China and is a resident of Shenzhen. Proficient in English and Japanese, she is an accomplished professional in the integrated television display and computer sector.
Nyxio Technology's Founder and CEO Giorgio E.W. Johnson comments, "We are excited to have Janny join us at this particular juncture in the growth of our Company. She brings a strong vision and outlook for growth into the fastest growing market for integrated display products in the world. With her relationships and track record in China we feel she is ready, willing and able to help Nyxio continue expanding its markets and organization in what is fast becoming the next big paradigm shift in consumer electronics. We look forward to her participation and extend our welcome to the team here at Nyxio Technologies."
Additional details regarding the Company, its business and its agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information visit: www.nyxio.com.
About Nyxio Technologies
Nyxio Technologies was established in 2007 to deliver high-quality, cutting-edge products to the consumer electronics industry. Nyxio identifies gaps in the market and develops creative products to fill those voids, such as the world�s first integrated flat screen TV and full PC, the VioSphere Smart TV. In addition, by consolidating key hardware into more efficient devices, Nyxio not only reduces the overall environmental footprint of end users, but keeps products reasonably priced. Headquartered in Portland, OR, Nyxio Technologies is a publicly traded company (NYXO) with more than 20 knowledgeable employees.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact:
Nyxio
Investor Relations
Summit IR Services, Inc.
Phone: 1-855-436-6996
investors@nyxiotech.com
MEDIA CONTACT
Angie Galimanis
503-546-7871
angie@lanepr.com

NYXIO TECH CORP (OTC: NYXO) is a showcase stock on Investorideas.com

Visit the company showcase profile page at www.investorideas.com/CO/NYXO

Get News and stock alerts for NYXO - Sign up here

Disclosure: NYXO is a showcase stock on Investorideas.com and the site is compensated three thousand per per month, third party, starting August 1, 2011

Renewable Energy Stocks Trading Alert; American Superconductor (NASDAQ:AMSC)
Trading up on News of Korea Electric Power Deal

Point Roberts WA-, 2011 (Investorideas.com renewable energy/green newswire)
Investorideas.com, a leader in cleantech investor research, issues a trading alert for American
Superconductor Corporation (NASDAQ:AMSC).The stocks is trading at $4.33, up 0.45 (11.60%)
2:16PM EDT, with a high on the day of $4.70.

Korea Electric Power Corporation (KEPCO), LS Cable & System and American Superconductor
Corporation (NASDAQ:AMSC) announced that the world’s longest distribution-voltage
superconductor cable system has been energized at the I’cheon substation located near the city
of Seoul. Powered by AMSC’s Amperium™ superconductor wire and installed in Korea Electric
Power Company’s (KEPCO) electricity grid, the 22.9 kV alternating current (AC) cable system
is capable of carrying approximately 50 megawatts of power. This is longest HTS cable in the
world to be energized in the grid utilizing second generation (2G) superconductor wire and is also
currently the longest distribution voltage superconductor power cable in operation.

“The energizing of the I’cheon substation has great historical significance and demonstrates
that Korean power electric technology is at a world-class level,” said Yup Heo, Executive Vice
President of KEPCO’s construction division. “Based on the technology and the know-how from
this installation, KEPCO will continue to develop transmission voltage superconductor power
cables and is securing the world’s top superconductor technology and market position.”

About American Superconductor (NASDAQ:AMSC )
AMSC offers an array of proprietary technologies and solutions spanning the electric power
infrastructure – from generation to delivery to end use. The company is a leader in renewable
energy, providing proven, megawatt-scale wind turbine designs and electrical control systems.
The company also offers a host of Smart Grid technologies for power grid operators that enhance
the reliability, efficiency and capacity of the grid, and seamlessly integrate renewable energy
sources into the power infrastructure. These include superconductor power cable systems,
grid-level surge protectors and power electronics-based voltage stabilization systems. AMSC’s
technologies are protected by a broad and deep intellectual property portfolio consisting of
hundreds of patents and licenses worldwide. More information is available at www.amsc.com.

Use the renewable energy stocks directory to research 1300 green stocks on
global stock exchanges http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

About Investorideas.com – a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable
energy stocks and has become a global go-to destination for investors researching the cleantech
sector, with stock directories, company news, commentary from experts, research reports and
industry resources and links. Investors can follow solar stocks commentary on our site with solar
expert, J. Peter Lynch.

Visit Investorideas.com green and renewable showcase stocks and more investor
research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or

www.renewableenergystocks.com

Investors - sign up for free green stocks trading alerts and news

http://www.investorideas.com/Resources/Newsletter.asp

Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks

Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees
as to the accuracy of information presented. All Information relating to featured companies is sourced from public
documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more:
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894

For more information about Investorideas.com contact:
800.665.0411

Consumer Electronic Stock News; Nyxio Technologies (OTCBB:NYXO) To Be Featured in Wall Street Journal Advertorial on September 28, 2011

MOLINE, Ill. - September 28, 2011 (Investorideas.com Tech stocks newswire) - A 16-page, full color insert highlighting Nyxio Technologies (OTCQB: NYXO) will be carried by The Wall Street Journal as an advertorial in select editions of tomorrow's paper, Wednesday, September 28th, 2011. The insert on Nyxio Technologies--a leading provider of quality cutting edge consumer electronics--has been authored by Eric Dany's Stock Prospector. The insert is available in select print editions.

Nyxio Technologies is committed to developing high-quality, cutting-edge products to the consumer electronics industry, including Smart TVs, Tablet PCs, and all-in-one PCs. Nyxio's Viosphere Smart TV is a touch screen device that is both a TV and a PC in one integrated package that will allow users to play video games, surf the web, download movies, use TV apps, visit social networking sites, send and receive email, and watch TV at the same time on a split screen. According to the DisplaySearch Q2'11 Quarterly TV Design and Features Report, connected TV shipments are forecast to grow to 138M units in 2015, accounting for 47% of all flat panel TVs shipped.
For more information on Nyxio Technologies Corp. visit www.NyxioTechnologies.com.
Nyxio's Other Products
Nyxio's OMEGA tablet is just one of the many products the company has on the market today. Other technologies currently include the VioSphere, a flat-screen TV with HDTV technology and a built-in personal computer and media center; the Realm, an all-in-one PC/TV; and the Venture Mobile Media Viewers (MMV), a new class of video eyewear.
About Prospector Newsletters and Eric Dany
The Prospector's charter is to provide simple, easy to follow, investment strategies providing solid, long-term results. Eric Dany has been investing for over 40 years. He has a BSME from Rose-Hulman Institute of Technology (1969) and MBA from the University of Florida (1979). Eric began publishing his newsletters in 1999. Since then he has successfully guided investors by applying an easy to use disciplined, quantitative investment process. He has been featured in articles appearing in CBS MarketWatch, The Kansas City Star, The Houston Business Journal, and Stephen Lord's "Wall Street Column" - Knight Ridder/Tribune Business News, among others.
About The Wall Street Journal
The Wall Street Journal ("WSJ") is published by Dow Jones & Company and is the top selling newspaper within the U.S. The WSJ has a 2.1 million average daily circulation, according to the Audit Bureau of Circulations' Fas-Fax circulation report covering the six months ended March 31. The WSJ primarily covers American economic and international business topics, and financial news and issues.
Disclaimer:
This paid advertisement by Eric Dany's Stock Prospector (hereafter "EDSP") does not purport to provide an analysis of any company's financial position, operations, or prospects and this is not to be construed as a recommendation by EDSP, or an offer to sell or solicitation to buy or sell any security. Nyxio Technologies Corp. (hereafter "NYXO"), the company featured in this issue, appears as paid advertising. Although the information contained in this advertisement is believed to be reliable, EDSP makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize it. The information contained herein is based exclusively on information generally available to the public and does not contain any material, non-public information. Readers should perform their own due-diligence before investing in any security including consulting with a qualified investment advisor or analyst. Readers should independently verify all statements made in this advertisement and perform extensive due-diligence on this or any other advertised company. Eric Dany has received a twenty thousand dollar fee from a third party for this advertising effort. Eric Dany/EDSP also expects to receive new subscriber revenue, the amount which is unknown at this time, as a result of this advertising effort. Eric Dany and EDSP nor any of their principals, officers, directors, partners, agents, or affiliates are not, nor do we represent ourselves to be, registered investment advisors, brokers, or dealers in securities. EDSP is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Research and any due diligence was conducted by an outside researcher for this advertisement. More information can be received from NYXO's website at www.nyxiotechnologies.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly listed companies and other investor resources can be found at the Securities and Exchange Commission website at www.sec.gov and www.nasd.com. Any investment should be made only after consulting with a qualified investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Many states have established rules requiring the approval of a security by a state security administrator. Check with www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. This advertisement is not intended for readers in any jurisdiction where not permissible under local regulations and investors in those jurisdictions should disregard it. Investing in securities is highly speculative and carries a great deal of risk, which may result in investors losing all of their invested capital. Past performance does not guarantee future results. The information contained herein contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the publisher notes that statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect the company's actual results of operations. Factors that could cause actual results to differ include, but are not limited to, the size and growth of the market for the company's products and services, regulatory approvals, the company's ability to fund its capital requirements in the near term and the long term, pricing pressures and other risks detailed in the company's reports filed with the Securities and Exchange Commission. Eric Dany's Stock Prospector is a trademark of Eric Dany. All other trademarks used in this publication are the property of their respective trademark holders. EDSP is not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by EDSP to any rights in any third-party trademarks.
About Nyxio Technologies
Nyxio Technologies was established in 2007 to deliver high-quality, cutting-edge products to the consumer electronics industry. Nyxio identifies gaps in the market and develops creative products to fill those voids, such as the world�s first integrated flat screen TV and full PC, the VioSphere Smart TV. In addition, by consolidating key hardware into more efficient devices, Nyxio not only reduces the overall environmental footprint of end users, but keeps products reasonably priced. Headquartered in Portland, OR, Nyxio Technologies is a publicly traded company (NYXO) with more than 20 knowledgeable employees.
Contact:
For Nyxio
LANE PR
Angie Galimanis, 503-546-7871
angie@lanepr.com
or
Nyxio
Investor Relations
Summit IR Services, Inc.
Phone: 1-855-436-6996
investors@nyxiotech.com

NYXIO TECH CORP (OTC: NYXO) is a showcase stock on Investorideas.com

Visit the company showcase profile page at www.investorideas.com/CO/NYXO

Get News and stock alerts for NYXO - Sign up here

Disclosure: NYXO is a showcase stock on Investorideas.com and the site is compensated three thousand per per month, third party, starting August 1, 2011